Dave Morris, MD
President, Therapeutics & Technology
Dave joined Valo as Chief Medical Officer in January 2022 and was promoted to President of Therapeutics & Technology that spring. Dave is responsible for enterprise-wide portfolio strategy and oversight and plays a critical role in integrating Valo’s therapeutic and technology capabilities with the design and development of our Opal Computational Platform™.
Dave has over 25 years of experience as a physician-scientist and global pharmaceutical executive with expertise across research, development commercialization, and venture financing. Previously Dave was the CMO of Enterprise Therapeutics and an Operating Partner of the Novartis Venture Fund. At Novartis, Morris also served as Global Head of Clinical Operations, Analytics, and Regions where he was responsible for clinical trials operations, monitoring, digital innovation, and data analytics. Prior, he was Development Franchise Head of Primary Care and Development Franchise Head of Respiratory. He has also held both discovery research and translational roles in academics and industry. Within Novartis and through the Novartis Venture Fund he has had founding and board-level roles in a series of companies, including a founding role of real-world data company TriNetX.
Dave received his BS in Neurosciences from the University of Rochester, his MD from the University of Rochester School of Medicine and Dentistry, and completed his Residency at Massachusetts General Hospital and Harvard Medical School. He maintains ABIM board certification in Internal Medicine, Pulmonary, and Critical Care Medicine.